ALK and non-small cell lung carcinoma: Interestingly, a report by Nakasuka and others demonstrated that treatment with a combination of bevacizumab, pemetrexed and platinum promoted sensitivity to alectinib in primarily resistant patient with advanced ALK-positive NSCLC.